From epilepsy to depression to Alzheimer’s, neurological conditions affect almost everyone. And people are desperately seeking solutions for themselves or someone they love. The Neurosciences Medicine (NSM) research program at the DCRI is dedicated to taking bold action to find these solutions.
Boldly Answering Today's
Driven by more than 40 psychiatry and neurology faculty, our program develops, conducts, and supports innovative phase I–IV clinical trials addressing neurological and psychiatric conditions for child, adolescent, adult, and geriatric patient populations.
Welsh-Bohmer to Lead Alzheimer’s Trials
Trained as a neuropsychologist, new DCRI faculty member Kathleen Welsh-Bohmer, PhD, focuses on prevention and treatment strategies to delay the onset of cognitive disorders occurring later in life.
New Digital Treatment
A new study led by the DCRI's Scott Kollins, PhD, suggests a digital treatment in the form of a video game specifically designed to improve attention could hold potential as a future treatment for the condition.
A New Model to Predict Alzheimer’s Progression
DCRI’s Sheng Luo, PhD and his co-authors have found that the novel combination of baseline information and longitudinal profiles of multiple clinical and neuroimaging markers can more accurately predict a patient's progression to Alzheimer’s disease.
- Rapid-start site network for neurosciences trials
- Biomarker development
- Cognitive endpoint design and assessment in clinical trials
- Control intervention development
- FAST-FAIL trial methodology
- Inpatient ICU trials (TBI)
- Neuroimmunology biomarker imaging studies
- Novel trial designs
- RDOC-based research
Comprehensive Experience in Neuroscience Research
We conduct industry and government-funded clinical projects of all sizes covering the full spectrum of neurosciences disorders, featuring projects in psychiatry and neurology for child, adolescent, adult, and geriatric patient populations.
Our research interests and capabilities are wide-ranging and include a focus on ADHD, autism, mood and anxiety disorders, epilepsy, sleep disorders, neuromuscular disorders, stroke, and neurodegenerative diseases. Our capabilities include:
- Early-phase PK/PD and POC trials, conducted in our onsite phase I unit
- Game and device/sham-controlled trial design and conduct
- Pediatrics (microdosing, PK)
- Neurocritical care trials
- Nerve conduction studies and electromyography
- Immune monitoring: mechanistic and predictive biomarkers
- Translational studies
- Large multisite trials
- Full-service CRO activities (protocol design/development, data management, biostatistics, pharmacokinetics, site management/monitoring)
Leadership at the DCRI
Daniel Laskowitz graduated from the Duke University School of Medicine. After completing his residency at Hospital of the University of Pennsylvania, he returned to Duke to complete his residency in cerebrovascular disease and neurocritical care.
Laskowitz's research interests include exploring new therapeutic interventions in the clinical setting of stroke, intracranial hemorrhage, and closed head injury. He is committed to translational research, and has several active clinical research protocols designed to bring the research performed in the Multidisciplinary Research Laboratories to the clinical arena.